Company intelligence
Maxion Therapeutics
Ion channel and GPCR drug discovery using innovative KnotBody technology
Biotechnology
Cambridge, GB
59 employees
Founded 2020
2 public signals
About Maxion Therapeutics
Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.
Verified activity
Signals from Maxion Therapeutics
2 published signals
Research & Knowledge
Maxion Therapeutics is discovering and developing an innovative new KnotBody drug candidate for chronic pain.
Reported by Arndt Schottelius, MD PhD
Products & Services
Maxion Therapeutics is developing KnotBody® therapeutics, a new class of biologics designed to effectively and selectively target pain relevant ion channels and GPCRs.
Reported by Maxion Therapeutics